Claudia Rosso Felipe

TL;DR: Sirolimus was associated with a reduction in the risk of malignancy and non-melanoma skin cancer in transplant recipients and the use of this drug does not seem warranted for most patients with kidney transplant.

TL;DR: Reduced‐dose tacrolimus and everolimus was associated with a significant reduction in the incidence of CMV infection/disease compared to standard tac rolimus dose and mycophenolate in de novo kidney transplant recipients receiving no pharmacological CMV prophylaxis.

TL;DR: Prolonged DGF, determined by retplantation and higher HLA mismatches, was associated with inferior renal function, and patient and graft survivals at one year, and Multivariable analysis showed that prolonged DGF was an independent risk factor for graft loss.

TL;DR: Traditional risk factors are still associated with transplantation outcome, and poorer graft survival in black vs nonblack patients was due to higher mortality rather than graft loss.

TL;DR: It is indicated that AcMPAG may contribute around 14% of the exposure to active drug after administration of MPA, and both EC-MPS and MMF treatments were well tolerated over the 1-month period of chronic treatment.